Education
About Us
Working with TipRanks
Follow Us
Ampio Pharmaceuticals (AMPE)
OTHER OTC:AMPE
RESEARCH TOOLSreports
AMPE Stock Chart & Stats
Day’s Range― - ―
52-Week Range<$0.01 - $0.13
Previous CloseN/A
Volume38.00
Average Volume (3M)490.00
Market Cap
$3.06K
Enterprise ValueN/A
Total Cash (Recent Filing)$4.09M
Total Debt (Recent Filing)$274.00K
Price to Earnings (P/E)―
Beta-3.98
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.09
Shares Outstanding1,135,358
10 Day Avg. Volume984
30 Day Avg. Volume490
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Ampio Pharmaceuticals News
AMPE FAQ
What was Ampio Pharmaceuticals’s price range in the past 12 months?
Ampio Pharmaceuticals lowest stock price was <$0.01 and its highest was $0.13 in the past 12 months.
What is Ampio Pharmaceuticals’s market cap?
Ampio Pharmaceuticals’s market cap is $3.06K.
When is Ampio Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Ampio Pharmaceuticals’s earnings last quarter?
Ampio Pharmaceuticals released its earnings results on May 11, 2023. The company reported -$0.264 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.264.
Is Ampio Pharmaceuticals overvalued?
According to Wall Street analysts Ampio Pharmaceuticals’s price is currently Overvalued.
Does Ampio Pharmaceuticals pay dividends?
Ampio Pharmaceuticals does not currently pay dividends.
What is Ampio Pharmaceuticals’s EPS estimate?
Ampio Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ampio Pharmaceuticals have?
Ampio Pharmaceuticals has 1,135,358 shares outstanding.
What happened to Ampio Pharmaceuticals’s price movement after its last earnings report?
Ampio Pharmaceuticals reported an EPS of -$0.264 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Ampio Pharmaceuticals?
Currently, no hedge funds are holding shares in AMPE
Company Description
Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.
Technical Analysis
Salarius Pharmaceuticals
―
Quoin Pharmaceuticals
―
Processa Pharmaceuticals
―
GRI Bio
―
Onconetix
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.04% Other Institutional Investors
99.96% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---